EML4 and non-small cell lung carcinoma: Rare ALK fusion genes have a far-reaching impact on the efficacy of ALK-positive TKI.[21] In patients with advanced ALK-positive NSCLC, some rare fusion genes may produce primary resistance to crizotinib, while others may be more effective than EML4-ALK fusion in ALK-TKI therapy.